Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HALO heads into its November 3 earnings with short sellers gradually reducing exposure, borrow conditions remaining relaxed, and options traders skewed firmly toward calls rather than hedges.
Short interest has been drifting lower for weeks, and that trend continued into early October. At 12% of the free float, the short position is still meaningful, but it has fallen roughly 2.7% on the week and nearly 2% over the past month. The direction of travel is clear: shorts are not pressing. The lending market tells the same story. Borrow costs have dropped more than 17% on the week to just 0.50%, a low level for a name carrying this much short interest. Availability is loose too, with nearly four shares available to borrow for every one currently lent out, well above the 52-week tightest point of 1.77 shares. There is no squeeze pressure here, and no sign that new shorts face friction in establishing positions. The ORTEX short score has also eased from 65 to 62.7 over the past week, moving in the same direction as the raw short interest figures.
Options positioning adds another layer to the bullish lean. The put/call ratio has been sitting around 0.46 over the past two sessions, well below the 20-day mean of 0.87. That means calls are outnumbering puts at roughly a two-to-one margin, a posture that leans more bullish than defensive heading into the next print. The ratio touched its 52-week peak of 3.65 briefly in late September, a spike that has now fully faded, and the current reading is much closer to the 52-week floor of 0.21.
The Street remains broadly positive. All four analysts tracked carry buy-equivalent ratings. After the August earnings beat, Leerink Partners upgraded to Outperform and lifted its target from $83 to $110, and TD Cowen and Wells Fargo also raised targets. HC Wainwright reiterated Buy at $115 as recently as September 2. With HALO trading at $109.72, the mean target sits in a tight band around the current price, meaning analysts who moved post-earnings have already largely been caught up to by the stock. The bull case centres on a second-quarter royalty haul of around $308 million, ENHANZE collaboration momentum, and a raised full-year guide. Bears point to roughly $2 billion in debt, heavy dependence on partner-driven royalties, and ongoing Merck litigation. The forward earnings-growth factor score of 93 reflects how far analyst estimates have moved, even as the value score remains low with the price-to-book above 8.5.
Earnings history gives context for what has moved this stock in the past. The most recent print, filed in early August, triggered a one-day gain of more than 23% and the stock held most of that move over the following five days. The prior quarter produced a much smaller one-day reaction of 1.6% but then rallied 25% over the week that followed. The pattern is not symmetric: when results please, HALO has tended to move substantially. Recent director activity on the register is worth noting, but carries little signal weight: Director Matthew Posard sold shares on both September 16 and October 1, all under a pre-arranged 10b5-1 plan, which schedules trades well in advance and does not reflect real-time conviction.
Wikipedia attention, the only alt data series available for HALO, registered a z-score of 3.18 against the stock's own 90-day history as of September 25. That is elevated retail attention relative to its own baseline. It is not a measured leading indicator for revenue, so it cannot be read as a directional signal for the November print, but it does suggest the stock has been attracting more eyes than usual in the weeks before results.
With shorts retreating, borrow loose, calls dominant, and the Street broadly constructive, the positioning heading into November 3 is one-directional enough that the reaction to the actual print, rather than any pre-earnings repositioning, is what to watch next.
See the live data behind this article on ORTEX.
Open HALO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
